QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults
QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine. AbbVie is the only pharmaceutical company to… Read More




